Nonpenetrating Deep Sclerectomy with Reticulated Hyaluronic Acid Implant versus Punch Trabeculectomy: A Prospective Clinical Trial

Russo, Vincenzo; Scott, Ingrid U.; Stella, Andréa; Balducci, Francesca; Cosma, A.; Barone, Antonio; Noci, Nicola Delle

doi:10.1177/112067210801800515

Cited by 42 publications

(55 citation statements)

References 20 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results are similar to the best data reported by several groups which carried out analogous GFS [24,25,[38][39][40] . Although our study included a small number of patients, no postoperative complications were observed, unlike other similar studies [41][42][43][44] .…”

Section: Discussionsupporting

confidence: 82%

Subconjunctival PRGF Fibrin Membrane as an Adjuvant to Nonpenetrating Deep Sclerectomy: A 2-Year Pilot Study

Rodríguez-Agirretxe

Freire²,

Muruzábal

et al. 2017

Ophthalmic Res

View full text Add to dashboard Cite

Purpose: To evaluate the potential role of the autologous PRGF (plasma rich in growth factors) fibrin membrane in tissue regeneration after glaucoma filtering surgery. Materials and Methods: Ten patients with medically uncontrolled primary open-angle glaucoma underwent nonpenetrating deep sclerectomy and were treated with PRGF fibrin membrane as adjuvant. Intraocular pressure reduction was the primary outcome. This variable was measured preoperatively and also at each follow-up visit. Secondary outcomes included the number of antiglaucoma medications, anterior segment optical coherence tomography bleb examination, photographic bleb evaluation, and subjective clinical symptomatology evaluation. Results: The surgical technique showed a significant reduction (p < 0.05) in intraocular pressure in relation to preoperative values at each time of the study, decreasing from 23.3 ± 6.4 to 15.2 ± 4.6 mm Hg at 2 years. Furthermore, the number of antiglaucoma medications consumed showed a significant reduction at the end point of the study compared with the preoperative situation. Optical coherence tomography and photographic filtering bleb variables experienced a progressive reduction during the follow-up. Subjective symptoms showed a reduction from 8.3 ± 4.5 to 4.2 ± 5.3 at 2 years. Conclusions: PRGF-Endoret treatment could promote ocular surface regeneration after glaucoma surgery, enhancing the surgery success rates and reducing the need for postoperative medications. It is important to highlight that this is a preliminary study and some large clinical studies are necessary to verify these results.

show abstract

Section: Discussionsupporting

confidence: 82%

Subconjunctival PRGF Fibrin Membrane as an Adjuvant to Nonpenetrating Deep Sclerectomy: A 2-Year Pilot Study

Rodríguez-Agirretxe

Freire²,

Muruzábal

et al. 2017

Ophthalmic Res

View full text Add to dashboard Cite

show abstract

“…Only long-term IOP reduction after 60 months was slightly lower in our study (33.2%) than in the study by Galassi et al (37.65%) [18]. Application of mitomycin during surgery by Russo et al did not have a significant effect on increasing the percentage of IOP reduction (38.3%) [26]. Reduction of applied medications was similar to that seen in the study by Rebolleda et al but lower than in the study by Galassi et al [18,24].…”

Section: Discussioncontrasting

confidence: 54%

Non-penetrating phaco-deep sclerectomy with SkGel implantation — long-term observations

Lewczuk

Jabłońska²,

Rudowicz³

et al. 2017

Ophthalmology J

View full text Add to dashboard Cite

introduCtion. The aim of this study is to present the efficacy and safety of non-penetrating phaco-deep sclerectomy (PDS) with implantation of an absorbable sodium hyaluronate implant (SkGel/Corneal). MATERIALS AND METHODS.In a prospective case series study 219 procedures were performed on 176 subjects receiving PDS with SkGel implantation. Indications were uncontrolled primary-open angle glaucoma (POAG) and operable cataract. Data collected included best corrected visual acuity (BCVA), intraocular pressure (IOP), and number of hypotensive medications. Follow-up examinations were performed one and seven days after procedure, then one, three, and six months after, and thereafter every six months. Complete and qualified success (without and with hypotensive medications) was assessed for IOP ≤ 18 mm Hg and IOP ≤ 12 mm Hg. resuLts. The mean follow-up was 48.3 ± 12.8 months. At 24 months, mean IOP decreased from 19.9 ± 5.0 mm Hg to 13.4 ± 3.1 mm Hg (P < 0.001) (31.8% reduction) and to 13.3 ± 2.7 mm Hg (P = 0.003) and after 60 months (33.2% reduction). At the 24-month follow-up, the average number of anti-glaucoma medications was reduced from 2.3 ± 0.8 to 0.62 ± 0.88 (p < 0.001). Complete and qualified success rates for IOP ≤ 18 mm Hg were 70.1% and 93.0%, respectively. Goniopuncture (23.8%), suturolysis (20.1%), and needling (18.3%) were performed. The most common complication was transient hypotony (36.07%). ConCLusions. PDS with SkGel leads to an effective decrease in IOP over a long-term follow-up. The profile of the complications indicates that it is a safe procedure.

show abstract

“…No eye in this study exhibited hypotony or flat/shallow anterior chambers. In comparison, the incidence of hyphema following trabeculectomy is reported in the range of 4-43% [18,[21][22][23] hypotony is reported in the range of 10-42% [20][21][22]24] and flat/ shallow anterior chambers are reported with an incidence of 13-43% [18,21,22].…”

Section: Discussionmentioning

confidence: 91%

“…3 Kaplan-Meier plot of the cumulative probability of failure for group 1 (CP or canaloplasty only with successful suture placement) and group 2 (PhacoCP or combined cataract-canaloplasty eyes with successful suture placement). Failure was defined as an IOP> 18 mmHg on two consecutive visits efficacy results are comparable to the lowest IOPs achieved in non-penetrating glaucoma surgery including viscocanalostomy [13][14][15], deep sclerectomy with various implants [16,17], and deep sclerectomy with adjunctive mitomycin C [18,19]. There is some rationale to believe that the addition of circumferential viscodilation and the trabecular meshwork tensioning suture in canaloplasty may provide an additional IOP lowering effect compared to the creation of a scleral lake and a Descemet's window alone, as is often achieved with deep sclerectomy or viscocanalostomy.…”

Section: Discussionmentioning

confidence: 99%

Three-year canaloplasty outcomes for the treatment of open-angle glaucoma: European study results

Bull¹,

Wolff²,

Körber

et al. 2011

Graefes Arch Clin Exp Ophthalmol

114

View full text Add to dashboard Cite

show abstract

Nonpenetrating Deep Sclerectomy with Reticulated Hyaluronic Acid Implant versus Punch Trabeculectomy: A Prospective Clinical Trial

Abstract: The IOP-lowering effects of the two procedures were comparable at 36 months. At 48 months PT showed a significantly higher rate of complete success compared with NPDS. Complications were more frequent after PT than after NPDS.

Cited by 42 publications

References 20 publications

Subconjunctival PRGF Fibrin Membrane as an Adjuvant to Nonpenetrating Deep Sclerectomy: A 2-Year Pilot Study

Subconjunctival PRGF Fibrin Membrane as an Adjuvant to Nonpenetrating Deep Sclerectomy: A 2-Year Pilot Study

Non-penetrating phaco-deep sclerectomy with SkGel implantation — long-term observations

Three-year canaloplasty outcomes for the treatment of open-angle glaucoma: European study results

Contact Info

Product

Resources

About